|
USA-329701-Refractories कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0 5 mg or 1 0 mg) or placebo for 104 weeks
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Population pharmacokinetics of semaglutide for type 2 diabetes Diabetes Ther 2019;10:649-662 Crossref PubMed New England Journal of Medicine Volume 392 • Number 20 • May 29, 2025
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type . . .
External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes, Expert Opinion on Pharmacotherapy, (1-8), (2025
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
New England Journal of Medicine Volume 385 • Number 6 • August 5, 2021 Pages: 503-515 Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes Download PDF Now Reading: Share
- Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is approved, at doses up to 1 mg administered subcutaneously once weekly, for the treatment of type 2 diabetes in adults and for
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 . . .
Cardiovascular disease is the primary cause of death in patients with type 2 diabetes, 1 and the ruling out of an excess cardiovascular risk is a regulatory requirement for new glucose-lowering
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Background: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of …
- Cardiovascular Outcomes with Oral Semaglutide in High-Risk Patients . . .
Randomized trials have shown that injected semaglutide lowers risk for adverse cardiovascular events in patients with type 2 diabetes (NEJM JW Gen Med Jul 1 2024 and N Engl J Med 2024; 391:109; NEJM JW Cardiol Nov 2016 and N Engl J Med 2016; 375:1834) To find out if the oral version confers similar benefit, researchers conducted an industry-sponsored randomized trial that involved nearly
|
|